Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

story of the week

Published in Obesity, Metabolic Syndrome, and Prediabetes and

Journal Scan / Research · December 01, 2021

Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity

The Lancet

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Caroline Apovian MD, FACP, FTOS, DABOM

The Lancet

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Lancet 2021 Nov 16;[EPub Ahead of Print], DCW Lau, L Erichsen, AM Francisco, A Satylganova, CW le Roux, B McGowan, SD Pedersen, KH Pietiläinen, D Rubino, RL Batterham

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity

Additional Info

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Further Reading

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction–Associated Steatotic Liver Disease

Once-Weekly Semaglutide in Individuals With Obesity and Knee Osteoarthritis

Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in Chinese Individuals

The Burden of Diabetes-Associated Multiple Long-Term Conditions on Years of Life Spent and Lost

Impact of GLP-1 Receptor Agonist–Based Treatments on Fat-Free Mass

Association Between Ultraprocessed Food Consumption and the Risk of Diabetes

Association of Glycaemic Risk Factors and Diabetes Duration With the Risk of Heart Failure in People With Type 2 Diabetes

Outcomes of Time-Restricted Eating in Adults With Metabolic Syndrome

Impact of Overweight and Obesity on Health Outcomes in the US From 1990 to 2021

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

Impact of GLP-1 RAs on Cardiorenal Outcomes and Mortality in People With Type 2 Diabetes and Acute Kidney Disease

Recently Updated